| __timestamp | Intra-Cellular Therapies, Inc. | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 54170000 |
| Thursday, January 1, 2015 | 18187286 | 65378000 |
| Friday, January 1, 2016 | 24758063 | 52263000 |
| Sunday, January 1, 2017 | 23666957 | 35072000 |
| Monday, January 1, 2018 | 30099855 | 27415000 |
| Tuesday, January 1, 2019 | 64947625 | 36983000 |
| Wednesday, January 1, 2020 | 186363444 | 50918000 |
| Friday, January 1, 2021 | 272611040 | 63586000 |
| Saturday, January 1, 2022 | 358782000 | 57967000 |
| Sunday, January 1, 2023 | 409864000 | 53107000 |
| Monday, January 1, 2024 | 23626000 |
Data in motion
In the competitive world of biotechnology, managing expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and Mesoblast Limited from 2014 to 2023. Over this period, Intra-Cellular Therapies saw a staggering increase in SG&A expenses, growing by nearly 3,900% from 2014 to 2023. In contrast, Mesoblast Limited's expenses remained relatively stable, with a slight decrease of about 2% over the same period.
The data reveals a strategic divergence: Intra-Cellular Therapies appears to be aggressively investing in its operations, while Mesoblast maintains a more conservative approach. This could reflect differing business strategies or market conditions. Notably, the data for 2024 is incomplete, highlighting the dynamic nature of financial forecasting in the biotech sector.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Intra-Cellular Therapies, Inc.
SG&A Efficiency Analysis: Comparing argenx SE and Mesoblast Limited
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Mesoblast Limited
Neurocrine Biosciences, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Catalyst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and MannKind Corporation
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Mesoblast Limited
Breaking Down SG&A Expenses: Veracyte, Inc. vs Mesoblast Limited
Breaking Down SG&A Expenses: Amicus Therapeutics, Inc. vs Mesoblast Limited
SG&A Efficiency Analysis: Comparing Mesoblast Limited and MannKind Corporation
Mesoblast Limited or Iovance Biotherapeutics, Inc.: Who Manages SG&A Costs Better?
Mesoblast Limited and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared